Clinical Trials Directory

Trials / Completed

CompletedNCT02431052

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

A Phase 2, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study of DRM01B Topical Gel in Subjects With Acne Vulgaris

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
420 (actual)
Sponsor
Dermira, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.

Conditions

Interventions

TypeNameDescription
DRUGOlumacostat Glasaretil
OTHERVehicle

Timeline

Start date
2015-04-01
Primary completion
2016-04-01
Completion
2016-04-01
First posted
2015-04-30
Last updated
2021-07-20
Results posted
2019-02-26

Locations

34 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT02431052. Inclusion in this directory is not an endorsement.

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris (NCT02431052) · Clinical Trials Directory